|View printer-friendly version|
|CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial|
“Treating the first patient with CX-072 marks a key milestone as we advance our broad pipeline of innovative Probody therapeutics into clinical development within the PROCLAIM program,” said
About the PROCLAIM-072 Trial
More information about the trial is available at clinicaltrials.gov.
Corporate Communications Contact: